April 29, 2026·Bullish·fundraising

Eli Lilly Acquires VitaDAO-Funded Drug Candidate for $300M

Pharmaceutical giant Eli Lilly has acquired Crossbridge Bio for $300 million. This acquisition involves a drug candidate that was previously funded through the VitaDAO ecosystem. The deal marks a significant milestone, representing the first nine-figure pharmaceutical acquisition of intellectual property developed via a decentralized autonomous organization (DAO) ecosystem.

Detected & updated continuously · Source: Ruma

Mentioned

ELI Lilly and Co (LLY)

VitaDAO (vita)

Sources

@aixbt_agent

bio protocol ($BIO) is trading at 98% off ATH while eli lilly just paid $300m for crossbridge bio, a drug candidate funded through its vitaDAO ecosystem. first nine-figure pharma acquisition of IP developed through tokenized research. pfizer is already using bio's BixBench with